Neubase Therapeutics Inc Stock News

NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is see

Penny stocks remain an alluring yet high-risk asset class for many novice investors. With share prices under $5, penny stocks appear affordable but bring higher volatility.

With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.

NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There are no new press releases from NeuBase Therapeutics

PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editi

NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy?

NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing.

NeuBase (NBSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NeuBase Therapeutics Inc (NASDAQ: NBSE ) announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1 (DM1), a multisystem disorder that affects skeletal and smooth muscle. A single intramuscular dose confirmed that NT-0231.F is pharmacologically active in the muscle and drives molecular and functional … Full story available on Benzinga.com

PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to

PITTSBURGH and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE ) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced that new preclinical data from its myotonic dystrophy type 1 (DM1) program will be featured in presentations at the 2022 MDA Clinical & Scientific Conference. MDA 2022 will be taking place virtually and in-person in Nashville, Tennessee, from March 13-16, 2022, and the abstracts will be available on the meeting website . Details of the presentations are as follows: Title: Pharmacology, Biodistribution and Tolerability of a PATrOL™-Enabled Investigational Genetic Therapy for Myotonic Dystrophy, Type 1 Type: Poster Presentation Date: Available for viewing Sunday, March 13 through Tuesday, March 15 Title: A PATrOL™- Enabled Investigational Genetic Therapy for DM1: Mouse Pharmacokinetics, Biodistribution, and CNS Penetration after Systemic Administration Type: Oral Presentation Date: Wednesday, March 16, 9:30am-9:45am CST Expanding upon initial data presented in June 2021, the presentations will include new data of a PATrOL™-enabled investigational genetic therapy for DM1.

NeuBase Therapeutics press release (NBSE): FQ1 GAAP EPS of -$0.24.As of December 31, 2021, the Company had cash and cash equivalents of ~$47.3M, compared with ~$52.9M as of September…